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Abstract
Background: A recent development in non-invasive techniques to predict intracranial pressure (ICP) termed
venous ophthalmodynamometry (vODM) has made measurements in absolute units possible. However, there has
been little progress to show utility in the clinic or field. One important application would be to predict changes in
actual ICP during adaptive responses to physiologic stress such as hypoxia. A causal relationship between raised
intracranial pressure and acute mountain sickness (AMS) is suspected. Several MRI studies report that modest
physiologic increases in cerebral volume, from swelling, normally accompany subacute ascent to simulated high
altitudes.
Objectives: 1) Validate and calibrate an advanced, portable vODM instrument on intensive patients with raised
intracranial pressure and 2) make pilot, non-invasive ICP estimations of normal subjects at increasing altitudes.
Methods: The vODM was calibrated against actual ICP in 12 neurosurgical patients, most affected with acute
hydrocephalus and monitored using ventriculostomy/pressure transducers. The operator was blinded to the
transducer read-out. A clinical field test was then conducted on a variable data set of 42 volunteer trekkers and
climbers scaling Mt. Everest, Nepal. Mean ICPs were estimated at several altitudes on the ascent both across and
within subjects.
Results: Portable vODM measurements increased directly and linearly with ICP resulting in good predictability (r =
0.85). We also found that estimated ICP increases normally with altitude (10 ± 3 mm Hg; sea level to 20 ± 2 mm
Hg; 6553 m) and that AMS symptoms did not correlate with raised ICP.
Conclusion: vODM technology has potential to reliably estimate absolute ICP and is portable. Physiologic increases
in ICP and mild-mod AMS are separate responses to high altitude, possibly reflecting swelling and vasoactive
instability, respectively.
Background
Several methods for non-invasive measurement of ICP
have been described but none have come to clinical use.
They include i) tympanic membrane displacement
(TMD) [1], ii) ultrasonic detection of skull pulsations
[2], iii) transcranial Doppler (TCD) ultrasonography of
the middle cerebral artery (MCA) [3-9], iv) visualization
of retinal venous pulsations [10], v) optic nerve sheath
diameter (ONSD) measurement by ultrasound [11], vi)
cochlear-microphonics [12], and vii) blood flow pulsa-
tions [13]. Small signal size and baseline variability
among healthy individuals, due in part to anatomic
variances affecting CSF communication between com-
partments, have limited the application of some of these
methods (e.g. TCD [14,15]; TMD [1]: and ONSD [16].
Moreover, they cannot provide absolute ICP prediction.
Central retinal vein (CRV) pressure measurements
quantifiably predict actual ICPs within a physiologic
range [17,18]. Increases in ICP directly affect the collapsi-
ble and valveless venous system draining the orbit into
the cavernous sinus. As brain pressure rises, so does the
resistance to retinal venous outflow. CRV pressure rises
proportionately to just overcome this ICP effect on out-
flow resistance. Venous ophthalmodynamometry
(vODM) is a method of manually raising intraocular ten-
sion (IOT) above the resting intraocular pressure (IOP),
to a point at which the central retinal vein is observed to
collapse. The pressure value at the point of collapse is
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(VOP) and is found to linearly predict absolute ICP. The
technique involves applying slight graded pressure to the
orbital sclera using a calibrated force transducer that
relies on either a compression-based spring gauge (see
below) or vacuum cup technology to manipulate intrao-
cular tension. Standard ocular tonometry and ophthal-
moscopy are additionally employed to derive resting IOP
and visualize the instantaneous moment of vein collapse,
respectively. We reported the calibration results of a pro-
totype venous ophthalmodynamometer in a unblinded
pilot study of 6 ICU patients [18]. vODM was found to
predict absolute intracranial pressure with a correlation
coefficient ~0.9. Nevertheless, the clinical utility of any of
these methodologies to predict actual ICPs awaits the
demonstration of a proportionate change to a continuous
physiologic variable.
Shared clinical symptoms and circumstantial evidence
suggest a causal relationship between raised intracranial
pressure (ICP) and acute mountain sickness (AMS). The
main symptom, headache, as well as nausea, anorexia,
fatigue and dizziness also overlap with migraine. The
pathophysiology of AMS is unknown, however intracra-
nial hypertension from cerebral swelling and hypoxia
has been suspected to be an important factor [19,20].
The mechanisms behind the underlying cerebral swel-
ling and variable vasogenic edema are postulated to be
cerebral vasodilation, increased blood flow (CBF) and
cerebral blood volume in combination with hydrostatic
pressure- and oxyradical or cytokine-induced blood
brain barrier (BBB) permeabilization [21-23]. However,
no studies to date have provided absolute ICP data as a
function of altitude and correlated this with AMS sever-
ity in the field. The extreme form of AMS, high altitude
cerebral edema (HACE), is associated with increased
ICP. Increases in cerebrospinal fluid (CSF) pressure
from 6 to 21 cm H20 above baseline were recorded in
one classical study [24]. Vasogenic edema in white mat-
ter structures, particularly the splenium of the corpus
callosum, were noted on MRI in another series of
HACE cases [25]. Whether the latter is causal of symp-
toms and intracranial hypertension or a correlated phe-
nomenon is not clear.
Although most MRI studies do not find signs of raised
ICP or generalized edema in normal subjects at simu-
lated altitude, changes occur to suggest mild global
brain swelling. MRI studies in non-exercised subjects
exposed to a simulated altitude of 4500 m (either nor-
mobaric hypoxia; FIO2 = 12% or hypobaric hypoxia; 429
mm Hg) for 16-32 hours show consistent increases in
brain volume, either global or grey matter specific,
across all subjects ranging from 0.6 - 2.7% [23,26,27]
and 1.1 - 5.8% [28]. This swelling arises from increased
cerebral blood volume (~7 cc) and/or parenchymal
water content (vasogenic edema) [27]. Some [22,29], but
not all studies [30], confirm the latter. Nevertheless, in
agreement with general swelling a compensatory 10%
reduction in CSF volume is observed in all subjects [30].
Taken together, these findings suggest that physiologic
swelling under hypoxic conditions may not be sufficient
to account for mild to moderate AMS symptoms. In
contrast, there is much less data on ICP changes with
altitude owing to the invasiveness of obtaining direct
numbers. Lumbar CSF pressures remained unchanged
or were inconclusive compared to normoxic values in
individuals at simulated 4500 m, with or without mild
-mod AMS [19,26,31]. In a single case with an
implanted telemetric ICP monitor at 5030 m, ICP
increased to upper normal levels at rest and further still
with exertion [32]. The question whether a physiologic
rise in absolute ICP accompanies the increase in cere-
bral volume and if this correlates with AMS symptoms
can be addressed with vODM.
The dual primary aims of this study were to validate
and calibrate a novel portable venous ophthalmodynam-
ometer and then use it to non-invasively estimate ICP
values in subjects at various altitudes, a test of the phy-
siologic response to hypobaric hypoxemia. Our pre-
viously reported venous ophthalmodynamometer was
modified and re-calibrated against a new set of neuro-
surgical patients, most with hydrocephalus, in the hospi-
tal setting. Actual or ‘gold standard’ ICP values were
recorded using conventional invasive catheters and con-
tinuous monitoring or from spinal tap at the time of the
non-invasive test. Additional validation involved training
several operators to collect the vODM data while
‘blinded’ to the actual ICP. We next conducted a clinical
field test on volunteer trekkers and climbers on the
approach to and at Camp 2, Mt. Everest, Nepal in 2007.
A secondary aim examined the relationship of ICP to
symptoms of AMS. We found that by vODM, ICP
increases physiologically with ascent.
Methods
Venous ophthalmodynamometry
vODM device
In compression-based vODM [18], force is transduced
through a miniature spring-loaded Differential Variable
Reluctance Transducer (DVRT®) (MicroStrain, Inc.
Williston, VT). Briefly, the spring provides a precise
counter force to the linear displacement of a plunger
core within a set of energized coils. This sensor unit has
a force resolution of approximately 0.5 milliNewton and
is housed within a smaller than pencil-sized, finger-held
probe. A signal-conditioningc a r dc o n v e r t st h el i n e a r
displacement into an output signal calibrated in grams
that is accurate to 1/10 gram. This sensitivity makes it
possible to record within the low range of pressures
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visible collapse of retinal venous outflow. The probe tip
that contacts the sclera is from polished stainless steel
(a convex, 6.3 mm dia. footplate) and is threaded for
easy removal and sterilization or disinfection in
chlorohexidine.
The prototype vODM was improved upon by: a)
powering it with two rechargeable Lithium polymer
(14.8 V, 2150 mAh) batteries. The electrical isolation
also made it convenient for patient contact in the ICU
and full portability into the field, b) designing a finger
activated button-type switch to freeze the display read-
out at the moment venous occlusion is reached and
then to reset it. This replaces the original foot petal
switch, making it possible to measure reclined subjects
at ground level. It was also found to improve the intra-
operator reliability of VOP measurements due to the
finer eye-hand control, c) enclosure within an IP67
environmentally sealed box (Additional file 1). It was
pretested over a temperature range of -4°C to 50°C by
calibrating the output voltage against the force (gms)
applied to an analytical balance. The relationship was
completely linear (1:1) with minimal drift (results not
shown).
Technique
The eye is first anesthetized with topical proparacaine
HCL (0.5%) and then dilated with Tropicamide (Mydria-
cyl, 1%), but neither is an absolute requirement. A single
resting intraocular pressure reading was obtained in all
subjects using a TonoPen tonometer (Reichert Co.) before
the ODM measurement. A Welsh-Allyn portable ophthal-
moscope was temporarily attached to the finger activated
freeze display switch. Next, the intraocular tension (IOT)
is incrementally elevated by graded application of the
ODM plunger to the lateral orbit (sclera) until one of the
retinal veins was observed to suddenly collapse through
the hand-held direct ophthalmoscope. The instantaneous
reading or venous occlusion pressure (VOP, load in
grams) is frozen using the finger-activated switch. From 3
to 5 repeat VOP readings are taken in rapid succession
(taking ~3 minutes) and averaged. The manually applied
pressure via the force transducer’sp r o b et i pi sl e s st h a n
generated when rubbing one’s own eyes (max < 60 g).
The instantaneous predicted absolute intracranial
pressure (ICP, mmHg) is derived from: 1) a linear
transformation of the applied force (gms) into the
resultant change in intraocular tension (IOT, mm Hg)
by using a published nomogram [18] that incorporates
a correction for the resting (baseline) intraocular pres-
sure and 2) a second simple conversion of the IOT (at
the VOP) into the predicted ICP based on the cali-
brated patient data. The previous reported ICP predict-
ability by this method was r ~ 0.9 (Pearson’s
coefficient of linear correlation) [18].
Clinical calibration and validation
Intra and inter-examiner accuracy
Reliability between serial measurements performed by
the same examiner on a given patient and in the same
environment is synonymous with ‘repeatability’ or ‘mea-
surement error’ as reflected in the standard deviation of
replicates. How accurate the instrument and technique
are in the hands of another operator is a measure of
‘agreement’. In previous work, the intra-examiner var-
iance in VOP measurements was ± 9% in the intermedi-
ate range of venous occlusion pressures (10-25 gms). The
inter-examiner variance in the means of replicates was ±
7% in control subjects [18]. In new studies involving nor-
mal subjects, we found the repeatability coefficient to be
3.9 gms (Additional file 2A), which corresponds to a 95%
confidence limit (2 SD) of ± ~ 4 mm Hg (after nomo-
gram conversion). The inter-observer agreement was
shown to be slightly less with a coefficient of 4.7 grams,
but is operationally acceptable given a less than 4 mm
Hg difference between the mean ICPs estimated by dif-
ferent operators on a given subject (Additional file 2B).
The pooled day-to-day variability among 3 additional
subjects tested over 2-3 days was calculated at a similar ±
4.8 gms (95% CI, results not shown).
Prediction of actual ICP
It was established in prior work [17,18] that ODM cali-
brates linearly with actual ICP measurements obtained
in critically ill patients using invasive cannulation and
continuous monitoring. So that the field readings taken
with the new device could be translated into absolute
ICP (mm Hg) with confidence, we repeated the standar-
dization in 12 hospitalized patients, most with hydroce-
phalus, requiring ventriculostomy or lumbar drainage
(n = 16 encounters).
Ventriculostomies were assembled for continuous ICP
monitoring with a calibrated pressure transducer set at
the foramen of Monroe. The indications were for the
management of hydrocephalus and intracranial hyper-
tension due to hemorrhage, tumor or trauma (Table 1).
Measurements were taken at 15° head elevation. Stable
absolute mean ICPs were required for at least 1 hour
before the non-invasive recordings were initiated.
Where ventriculostomy provided the ‘gold standard’ ICP
value, vODM were carried out in the ‘open to drainage’
position and clamped when possible, providing thus two
points. The vODM procedure was carried out under
institutional review board (IRB) approval following
HIPAA guidelines and informed consent protocol. Sub-
jects were excluded if they had carotid occlusion or
severe stenosis, retinal disease, corneal opacification or
acute glaucoma. Other grounds for exclusion were if the
patient could not be positioned at 15° due to pressure
support or if the subject could not maintain ocular fixa-
tion for any reason. While thep r e s e n c eo fp a p i l l e d e m a
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2. The VOP measurements (in gram units of load) were
collected by one of 3 trained operators who were
‘blinded’ with respect to the medical details and actual
ICP. An ICU nurse or assistant obscured the monitor
from the operator’s view and recorded the mean ICP
and print out of the ICP waveform for placement in a
sealed envelope with the neurosurgery study coordina-
tor. At the end of the study, the seal was ‘broken’ with a
collaborating neurosurgeon present.
High Altitude Measurements
vODM and subjects
On the southwestern approach to and South Col route on
Mt. Everest (Nepal), we performed ODM measurements
on 42 volunteers (a ‘convenience set’), including multiple
altitudes on 9 subjects. This research plan was part of a lar-
ger Brown University sponsored study in 2007 tracking
cognitive and speech-motor control deficits at extreme alti-
tude which was approved by the Nepal Health Research
Council (NHRC). There were no exclusionary criteria as to
age, sex, nationality or use of medications. All subjects
were fluent in English and a similar disclosure and signed
consent protocol was followed. The indigenous local popu-
lation was not tested due to language barriers, their lifelong
adaption to altitude and multiple ascent/decent profiles. At
each climber-clinician encounter, a rapid succession of
non-invasive vODM ICP readings (3-5) was obtained and
an AMS/headache scale score was assessed by the operator
(Lake Louise Consensus on Definition of Altitude Sickness,
1991. http://www.high-altitude-medicine.com). Thus, the
investigator was not blinded to the AMS scoring. Tests
were performed at sea level, in Kathmandu and at various
stations up to and including upper base camp (17,500 ft
5400 m) and upper camp 2 (21,500 ft, 6600 m). They were
made within 48 hours of arrival and on the ascent profile
to a particular altitude.
The conversion from the VOP to estimated ICP
requires a correction for the resting intraocular pressure
[18]. Therefore, the rest IOP was obtained on all volun-
teers, before the intraocular tension (IOT) was mechani-
cally increased. To reduce bias in making repeated
intrasubject measurements, raw data was transcribed by
a student assistant and the records not analyzed for ICP
estimation until the conclusion of the study. The ICP of
each individual at a given altitude station was estimated
using first a published nomogram (Figure one in [18])
which converts the pressure applied to the eye (grams)
to the resulting intraocular tension (mmHg). The IOT
corresponding to the pressure at the point of CRV col-
lapse is the VOP (mmHg). The ICP is then estimated
from this VOP value using published correlation data
(Figure three A in [18]) or in the case of this study, the
calibration plot shown in Figure 1 (see also Figure four
in [17]) (calculations not shown).
Psychometric Test
In a sub-aim of this study, a verbal-auditory word recall
test was used to rapidly assess working memory (Additional
Table 1 Patient Characteristics
Pt Age/sex Diagnosis ICP method MAP mean IOP ICP mean VOP (sd) NIHSS/GCS
1 71 M NPH Lumbar drain, intraoperative 98 15 11.7 17.4 (4.7) 0/15
2 53 M R. temp ICH, craniotomy Ventriculostomy. 97 10 7.0 (open)
22.5 (closed)
9.2 (1.0)
21.8 (2.8)
40×/5
3 61 M Cerebell ICH Ventriculostomy 108 4 11.0 (open)
40.6 (closed)
11.7 (2.4)
35.0 (3.3)
40×/3
4 61 F Obstruct. HC TBI: IVH,SAH VP shunt, intraoperative 89 15 8.8 11.8 (0.9) 1/14
5 83 F NPH VP shunt, intraoperative 102 21 13.2 23.8 (2.4) 0/15
6 46 M Obstruct. HC congenital VP shunt, intraoperative 102 14 25.0 31.5 (6.2) 0/15
7 53 M R.temp-parietal ICH,IVH, craniotomy Ventriculostomy 112 6 17.0 (open) 21.0 (4.5) 20/13
8 51 M Communic. HC old TBI Lumbar puncture 76 23 23.5 25.8 (3.9) 0/15
9 42 F Vermis tumor, craniotomy Ventriculostomy 105 7 10.0 (open) 10.9 (2.9) NA/12
10 52 M R. frontal contusion, TBI ICP monitor 96 13 1.0 7.1 (1.6) NA/6
11 22 M Meningitis, acute HC Ventriculostomy 110 10 24.0 (open) 20.6 (2.8) 42/4
33.0 (closed) 26.9 (2.9)
9.0 (open) 12.2 (0.7)
12 50 M L. pariet-occip AVM: ICH,IVH Ventriculostomy 73 14 11.5(closed) 13.4 (3.9) 2/14
Notes: All patients, except no. 10, evidenced hydrocephalus on brain imaging studies. Mean arterial, intraocular, intracranial and VOP pressures are in mm Hg.
n = 16 observations, 8 O.D., 8 O.S.
Abbreviations: MAP: mean arterial pressure, IOP: intraocular pressure (resting), ICP: intracranial pressure, VOP: central retinal venous occlusion pressure, sd 1
standard deviation, NIHSS: Nat. Instit. Health Stroke Scale, GCS: Glasgow Coma Scale, NPH: normal pressure hydrocephalus, HC: hydrocephalus, AVM:
arteriovenous malformation, VP: ventriculoperitoneal, TBI traumatic brain injury, IVH: intraventricular hemorrhage, SAH: subarachnoid hemorrhage, ICH: intracranial
hemorrhage, O.D., O.S.: oculus dexter and sinster, NA not available.
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of 21 simple familiar words in 30 seconds. Immediately
thereafter, they were asked to recall all 7 words that con-
formed to a specific category. The specific category for each
trial was presented to the subject before the list was read.
He/she was instructed to ignore the extraneous words
when responding. Four such lists were used. If the same
subject was tested at more than one altitude, he/she was
presented an alternate list. The four strategies were to recall
words: beginning with the letter B, corresponding to the
quality of being round, denoting a tool and categorized as
an action or verb. At sea level, normal young adults
achieved a mean of 6.0 ± 0.2 words irrespective of the parti-
cular list. The test is similar to the item category recall por-
tion of the CVLT; the usual score is similar to that of other
short word list tests (e.g. mean 5.6 [33]).
Statistical Considerations
The VOPs from calibration vODM measurements per-
formed on ICU patients were fitted to the response vari-
able (absolute ICP) using standard linear regression by
least squares. The VOP of climbers was correlated to
altitude and AMS score in like fashion. A calculation for
the number of observations required to power (1-b)t h e
ICP vs. altitude Everest field study at .90 (a = .05) came
to n = 42. It is based on the previously obtained Pearson
correlation coefficient of 0.89, a p = .05 level of signifi-
cance and a conservative inter-examiner and intra-
subject variation of 9 mm Hg. A clinically important
difference to detect was taken as 10 mm (effect size).
For this study, Bland-Altman plots were used to evaluate
repeatability and agreement [34-36] (Additional file 2A
and 2B). vODM accuracy to discriminate normal from
elevated ICP was assessed by constructing receiver
operator characteristic (ROC) curves (GraphPad Prism
Inc. statistical software).
Results
The vODM device as depicted in Additional file 1 was
calibrated using 12 hospitalized patients in the neuroICU
or operating room and in whom ICP determination or
monitoring was deemed medically necessary for such
conditions as are noted in the Table 1. Most had hydro-
cephalus: 2 obstructive (decompensated congenital, suba-
cute due to TBI), 2 idiopathic NPH, 2 communicating
(decompensated old TBI, acute meningitis), and 4 with
intracranial hemorrhage. In addition, 1 patient was post
midline tumor resection and 1 had acute TBI with cere-
bral contusion. The conventional mean ICPs recorded
from the transducers ranged from 1.0 to 40.6 mm Hg.
The results summarized in Figure 1A were independently
collected by three operators working in separate institu-
tions, who were blinded to the simultaneous actual ICPs.
The mean of 3-5 rapid, successive non-invasive ODM
Figure 1 Validation of vODM. A.O D Mm e a s u r e m e n t so ft h e
venous occlusion pressure (VOP, mmHg) conform linearly with
actual ICP measurements made in critically ill patients with invasive
canulation and continuous monitoring or taken in the OR at time of
shunting or obtained through lumbar puncture. 12 patients with
acute or decompensated hydrocephalus from various etiologies
(intracranial hemorrhage n = 4, obstructive n = 2, ‘NPH’ =2 ,
communicating n = 2) and 1 each with acute trauma and midline
tumor removal, underwent either ventriculostomy or lumbar
puncture. They were measured in a total of 16 encounters by either
of 3 operators who were blinded to the actual instantaneous ICP.
The recorded ICPs ranged from 1.0 to 40.6 mm Hg. The individual
points are the mean of 3-5 rapidly successive ODM readings of the
VOP (mmHg) plotted against a single actual ICP reading (the fitted
line is ICP = 1.07 VOP- 4.6; r = 0.85; (- - - -) denote 95% confidence
limits). B. ROC curve for vODM data in A. Area under curve (AUC) is
0.89 (95% CI 0.73-1.05, p < .01).
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correlated to the actual ICP (r = 0.85). This calibration
confirms our earlier unblinded results [18] and are also
very similar to the correlation published by another
group using ODM, but on different instrumentation [17].
The ROC curve for this data set using ICP>15 mm Hg as
the cutoff denoting elevated ICP, indicates a relative
accuracy of 0.89 (area under curve; 95% CI is 0.73-1.05)
to predict raised ICP (Figure 1B).
We next tested 42 trekkers and climbers on the ascent
of Mt. Everest at various altitudes for a total of 54 VOP
measurements. These were performed at elevations ran-
ging from sea level to base camp (17,500 ft, 5400m) and
at camp 2 (21,500 ft, 6553 m). First we found that the
resting IOP did not change appreciably with altitude
(Figure 2). This result is consistent with a very small
reported change in mean IOP within 1-3 days after
attaining 5200 m (from 11.4 to 12.4 mm Hg) [37].
Therefore, its overall effect on the CRV- and ICP-pres-
sure correlation was minimal.
Next, we applied vODM to mechanically increase the
intraocular tension to find the retinal venous occlusion
pressure (VOP). The ICP at any given altitude and sub-
ject is estimated from the resting IOP and a nomogram
converting the VOP into the corresponding induced IOP
(mmHg) and a second linear transformation relating this
to actual ICP (Figure 1). Compared to sea level measure-
ments performed on young adults, in which the mean
ICP was ~10 mm Hg, there was a clear trend for mean
ICP to rise with elevation, reaching significance starting
at 3445 m (Namche Bazaar)(p < .005). The mean
estimated ICP at Camp 2 (6553 m) was ~20 mm Hg. A
linear model as shown in Figure 3A, results in a calcu-
lated r = 0.88. Alternatively, there may be a leveling-off
of ICP after 4300 m. Further studies involving higher ele-
vations may be necessary to resolve this latter point.
H o w e v e r ,h y p o x i ai sl i k e l yt ob eam a j o rf a c t o ri nt h i s
response and as expected, oxygen desaturation is signifi-
cant at basecamp and progressively worsens with ascent
to Camps 2 and then 3 in a subset of climbers (Figure
3A, inset). Among individual subjects that underwent
repeat testing at different elevations, the trend also
reflected an increase at the higher elevation (Figure 3B).
A l m o s to n eh a l fo fa l lv o l u n t e e r sh a do n eo rm o r e
symptoms of acute mountain sickness. Corresponding to
mild severity, these ranged in symptom score from 1-9
(Lake Louise criteria, see methods). When plotted against
the predicted ICP at the time of assessment, there was lit-
tle evidence for correlation (Figure 4; r = .05).
Discussion
These results support the feasibility that absolute ICP can
be estimated and that non-invasive vODM has practical
utility by showing changes that correlate predictably with
a relevant physiologic variable (hypoxia). To our knowl-
edge, these preliminary studies are the first to use
ophthalmodynamometry in the high altitude setting. We
improved upon our earlier calibration and validation stu-
dies of vODM in using a new set of ICU patients under a
‘blinded’ protocol. This approach to non-invasive ICP
measurement is relatively direct because the level of
induced intraocular pressure where the retinal vein is
seen to collapse, is an unequivocal dynamic endpoint.
There is also a direct relationship to the pressure in the
intracranial compartment into which the venous retinal
blood flow has to return. These properties make the pre-
diction of ICP in absolute mm Hg possible.
Although there is considerable individual variation, the
general increase in intracranial pressure with altitude
probably represents a universal physiologic response to
hypoxia. This is in agreement with previous MRI find-
ings of cerebral swelling [38,39]. The mechanisms
behind the cerebral intravascular expansion and/or vaso-
genic edema are not known. Hypoxia is suspected to sti-
mulate cerebral blood flow (and to increase brain blood
volume) but this literature is contentious. Simulated alti-
tude studies show CBF increases acutely after attaining
elevations up to 4559 m [40-44]. Others found no
change [45-47]. Variances in vascular reactivity (e.g.
controlling for exercise) and cerebral blood vessel auto-
regulation (e.g. controlling for systemic blood pressure)
m a yu n d e r l i es o m eo ft h e s ed i fferences. BBB disruption
due to hypoxemia and reactive oxyradical stress [21,23]
has been implicated in edema formation. However, no
changes in vascular permeability or cerebral edema
Figure 2 Resting intraocular pressure. Before introcular tension is
raised by the ODM to determine the additional pressure required to
observe the collapse of the central retinal vein, the baseline
intraocular pressure (IOP) is taken from a tonometer reading. For
every ODM measurement in the Mt. Everest cohort, these are
plotted against elevation. There is no significant correlation of mean
IOP with change in altitude. Values in mm Hg are ± 1 SD.
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Page 6 of 11Figure 3 Predicted ICP generally increases with elevation. A. A total of 42 normal adult volunteer subjects were administered from 1 to 3
ODM measurements at varying elevations for a total of 54 encounters. Altitudes ranged from sea level (15 m) to upper basecamp on the
Everest trek (5400 m) and upper Camp 2 (6600 m) on the mountain. From these measurements, the resting tonometry results of Figure 3. and
published nomogram [18], the estimated ICP was calculated (mm Hg). Each point represents the mean of 3-5 readings from a given encounter,
averaged again over the number of individuals (n) measured at the elevations shown below. Bars are ± 1 SE. By linear regression, r = 0.88. Mean
ICP at sea level was 10.0 ± 3.4 (SD, n = 6), at Namche Bazaar (3445 m) was 16.5 ± 4.7 (n = 10, p < .005), at basecamp was 19.3 ± 4.1 (n = 11,
p < .001) and at Camp 2 was 19.8 ± 2.1 (n = 5, p < .001). Resting oxygen saturations and pulse (± SD) were obtained at sea level (15 m, n = 6),
r=0.87; basecamp (5400 m, n = 7), Camp 2 (6553 m, n = 7) and Camp 3 (7200 m, n = 5) indicating progressive hypoxia. B. Individual variations
in mean calculated ICP are plotted where the same subject underwent repeat measurement at a higher elevation. N = 9 subjects for a total of
12 interval changes. The interval difference is denoted with + (increase) or - (decrease).
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hypoxic chamber - AMS study [26]. Moreover, one
hypoxia-induced angiogenic factor that promotes capil-
lary leakage, VEGF [48-51], has been excluded of asso-
ciation with either hypoxia or AMS [26]. Exhaled levels
of the vasodilator nitric oxide (pNO) decrease with alti-
tude but also fail to correlate with AMS symptoms [52].
Importantly, no correlation with AMS was found in
most of the above studies, with only 2 exceptions
[41,53]. Similar to the MRI studies on brain volume, we
found no relationship of the increase in ICP to the inci-
dence or severity of mild-mod AMS symptoms. Alterna-
tively, the etiology of headaches could reflect vasoactive
instability but does not exclude a lesser contribution
from cerebral swelling and rise in ICP. Indeed, a less
compliant ventricular CSF system is proposed to predis-
pose AMS [32]. Chemical mediators, such as NO and
arachadonic acid metabolites, activate trigeminovascular
system pain fibers which travel in proximity to menin-
geal blood vessels [54]. In combination with mechanical
stretch from local edema or intracranial hypertension
(ICH), this migraine-like hypothesis may explain indivi-
dual responsivity to anti-migraine therapies for AMS
such as NSAIDS [55], sumatriptan [56-58] and analge-
sics (personal observation).
Another disabling symptom of high altitude, cognitive
impairment, particularly working memory and executive
control, is reported in human [59] and rodent [60-62]
studies. Various hypoxic conditions (e.g. sleep apnea,
exhaustive exercise) are associated with reductions in
prefrontal oxygenation or activation [63-65]. Working
memory impairment at altitude is consistent with fron-
tal-subcortical vulnerability to hypoxia [66,67]. There is
no data on whether ICP has any independent effect on
frontal-based functions. We found a general decline in a
working memory test at the two highest elevations (Addi-
tional file 3A). Although the result is expected, there was
great variability among subjects. Similarly, we found only
weak negative correlation between test performance and
estimated ICPs (r = 0.64, Additional file 3B).
Our study confirms one aspect of an older [68] and
more recent non-invasive study on Mt. Everest that
used a very different ocular technique [69]. Optic
nerve sheath diameter (ONSD) assessment by ultra-
sound showed increases in optic nerve diameter with
altitude up to 6400 m (21,000 ft). Since nerve sheath
diameter is an indirect indicator of ICP [16], the
authors conclude, as we do, that brain pressure natu-
rally rises. However, they and recently another group
[70] oppositely report a positive correlation with mean
AMS scores, concluding that ICP increases are a major
factor in AMS pathophysiology.
All non-invasive techniques have limitations. ONSD
values are relative and not calibrated to actual ICP.
Moreover, intrathecal infusion tests show that ONSD
responses are linear only between 22 and 30 mm Hg [16]
and in ICU patients, the scatter in ONSD vs. ICP yielded
a correlation coefficient of 0.59. A cut-off of 5 mm
ONSD was determined to provide a relative assessment
of ICPs > 20 cm H2O [71]. Regarding ODM measure-
ments, changes in retinal blood flow at altitude could in
theory confound the interpretation of VOP measure-
ments. Indirect estimates at 17,500 feet [72] or more
direct flow measurements but after descent [73], suggest
such increases can occur. Thus, increasing VOPs at
higher altitude may reflect a combination of ICP and
increasing blood volume in the retinal venous circuit.
How retinal blood flow and volume affect ODM mea-
surements is an important relationship to establish in
future research. Another variable possibly affecting both
techniques is that local interstitial edema, as may involve
multiple body organs at high altitude, could affect either
ONSD or ocular vascular pressure readings independent
of brain pressure. Assessment of this contribution under
field conditions posses another challenge.
Several limitations of our pilot altitude study are
acknowledged. First, the readings were not ‘blinded’
since they were collected while the examiner was aware
of the altitude and AMS score. Our study, unlike the
ONSD report, was not a longitudinal one by design. It
was carried out on a variable dataset consisting of a
small number of volunteers (≤10) at most altitudes.
Together with the primitive or extreme conditions, a
low number of measurements is understandable. Had an
even larger proportion of our subjects been repeatedly
measured at various altitudes, a greater power of statisti-
cal association may have been obtained. These issues
and the differences in the role of ICP as a factor in
Figure 4 AMS symptom score vs. estimated ICP.2 2v o l u n t e e r s
had AMS symptoms ranging from 1 (e.g. mild headache) to 9 (e.g.
incapacitating headache with nausea, dizziness and sleep
disturbance). AMS plotted against ICP shows a relative lack of
correlation (r = 0.05).
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data could be resolved through a larger trial on a single
cohort. Other features to build into subsequent studies
are to manipulate ICP (e.g. increase PaCO2 or 02)[ 7 4 ] ,
potentially treat AMS and make additional measure-
ments on the descent phase. Nevertheless, our study
affords a practical approach to AMS evaluation by
proof-of-principle that a symptomatic individual can be
spot evaluated for actual ICP.
Conclusion
vODM is a safe and validated method to predict ICP as
shown in this new blinded study of hospitalized patients
with acute or decompensated hydrocephalus of varying
etiologies. Validation for field use was explored in a
small sample of normal volunteers under hypobaric
hypoxic conditions. In this pilot study of trekkers and
veteran climbers on Mt Everest, there is evidence for a
significant general increase in intracranial pressure with
altitude. However, this moderate increase did not appear
to be causal in the occurrence of mild to moderate
acute mountain sickness.
Additional material
Additional file 1: Schematic and actual venous
ophthalmodynamometer (ODM). The finger button-activated freeze
display and reset switch is shown tethered to the device on the far right.
The force transducer (DVRT- eye pressure sensor) is shown over the
circuitry board, center right, with attached scleral footplate and cable.
Two 14.8 V Lithium cells are seen to the left, below a transparent
protective seal from Lucite. The liquid crystal display readout is calibrated
in grams. View of Western Cwm, Camp 2 in the foreground, Lhotse
center, shoulders of Everest (left) and Nuptse (right).
Additional file 2: Validation studies. A. Repeatabilty is the accuracy
with which an operator obtains the same venous occlusion pressure
(gms) while making multiple measurements on the same subject. Results
from 2 subjects are shown. 10 single measurements of subject A over 3
days netted a mean of 7.1 gms. The average of 12 back-to-back
measurements on another subject B was 10.1 gms. The differences from
the means are plotted. The 2SD levels indicate the repeatability
coefficient of 3.9 gms (95% confidence limits). B. Reproducibility is the
accuracy with which 2 operators agree on VOP measurements.
Interobserver differences in paired measurements from the pooled mean
are plotted for 3 new subjects, A, B, and C. Operator no.1 was compared
with no.2 for the first two subjects and operator no.1 compared to a
third (no. 3) for subject C. The respective means obtained by each
operator (force, grams), blinded to the results of the other, are given
below and indicate good agreement (coefficient = 4.7 gms). Bland-
Altman plots.
Additional file 3: Working memory and altitude. A. In a preliminary
assessment of this executive cognitive function at increasing altitude, all
subjects were administered a 30 sec word recall test involving the
immediate recall of a best of 7 in-category words from a read list of 21.
The test always followed the ODM exam. Performance varied
considerably between individuals but trended downward at basecamp
and higher elevation (±1 SD). B. Mean word recall at increasing intervals
(2 mmHg) of estimated ICP also show a downward trend, but not
reaching significance.
Abbreviations
ICP: intracranial pressure; vODM: venous ophthalmodynamometry (-meter);
CRV: central retinal vein; ON: optic nerve; AMS: acute mountain sickness;
HACE: high altitude cerebral edema; WM: working memory; IOP: intraocular
pressure; ICH: intracranial hypertension; VOP: venous occlusion pressure; CSF:
cerebral spinal fluid; PFC: prefrontal cortex; TBI: traumatic brain injury.
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